GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (FRA:LWB) » Definitions » Cyclically Adjusted Price-to-FCF

Mesoblast (FRA:LWB) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mesoblast's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Cyclically Adjusted Price-to-FCF Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mesoblast's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mesoblast's Cyclically Adjusted Price-to-FCF falls into.



Mesoblast Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mesoblast's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Mesoblast's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Mesoblast Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 0.000 98.352 0.000
201412 0.000 99.002 0.000
201503 0.000 99.187 0.000
201506 0.000 99.838 0.000
201509 -0.072 100.302 -0.091
201512 -0.048 100.673 -0.060
201603 -0.049 100.488 -0.062
201606 -0.040 100.859 -0.050
201609 -0.047 101.602 -0.058
201612 -0.060 102.159 -0.074
201703 -0.057 102.624 -0.070
201706 -0.046 102.809 -0.057
201709 -0.037 103.460 -0.045
201712 -0.025 104.110 -0.030
201803 -0.032 104.574 -0.039
201806 -0.035 104.945 -0.042
201809 -0.033 105.410 -0.040
201812 0.003 105.967 0.004
201903 -0.036 105.967 -0.043
201906 -0.032 106.617 -0.038
201909 -0.027 107.174 -0.032
201912 -0.003 107.917 -0.004
202003 -0.033 108.289 -0.039
202006 -0.022 106.246 -0.026
202009 -0.039 107.917 -0.046
202012 -0.001 108.846 -0.001
202103 -0.033 109.496 -0.038
202106 -0.023 110.332 -0.026
202109 -0.023 111.168 -0.026
202112 -0.024 112.654 -0.027
202203 -0.021 115.069 -0.023
202206 -0.019 117.112 -0.021
202209 -0.020 119.248 -0.021
202212 -0.020 121.477 -0.021
202303 -0.020 123.148 -0.021
202306 -0.018 124.170 -0.018
202309 -0.016 125.656 -0.016
202312 0.000 126.399 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast  (FRA:LWB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mesoblast Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mesoblast's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (FRA:LWB) Business Description

Industry
Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Mesoblast (FRA:LWB) Headlines

No Headlines